AI assistant
Acumen Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 20, 2024
34208_dirs_2024-01-19_1376a72d-ccd2-48b9-8bd6-81c19737df4b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2024-01-18
Reporting Person: Barton Russell (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-18 | Common Stock | S | 2833 | $3.7258 | Disposed | 96867 | Direct |
Footnotes
F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2023.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.7250 to $3.7300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.